Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor

以[18F]FDG PET/CT肝脏SUV作为参考或归一化因子的可重复性

阅读:1

Abstract

INTRODUCTION: Although visual and quantitative assessments of [18F]FDG PET/CT studies typically rely on liver uptake value as a reference or normalisation factor, consensus or consistency in measuring [18F]FDG uptake is lacking. Therefore, we evaluate the variation of several liver standardised uptake value (SUV) measurements in lymphoma [18F]FDG PET/CT studies using different uptake metrics. METHODS: PET/CT scans from 34 lymphoma patients were used to calculate SUVmax(liver), SUVpeak(liver) and SUVmean(liver) as a function of (1) volume-of-interest (VOI) size, (2) location, (3) imaging time point and (4) as a function of total metabolic tumour volume (MTV). The impact of reconstruction protocol on liver uptake is studied on 15 baseline lymphoma patient scans. The effect of noise on liver SUV was assessed using full and 25% count images of 15 lymphoma scans. RESULTS: Generally, SUVmax(liver) and SUVpeak(liver) were 38% and 16% higher compared to SUVmean(liver). SUVmax(liver) and SUVpeak(liver) increased up to 31% and 15% with VOI size while SUVmean(liver) remained unchanged with the lowest variability for the largest VOI size. Liver uptake metrics were not affected by VOI location. Compared to baseline, liver uptake metrics were 15-18% and 9-18% higher at interim and EoT PET, respectively. SUV(liver) decreased with larger total MTVs. SUVmax(liver) and SUVpeak(liver) were affected by reconstruction protocol up to 62%. SUVmax and SUVpeak moved 22% and 11% upward between full and 25% count images. CONCLUSION: SUVmean(liver) was most robust against VOI size, location, reconstruction protocol and image noise level, and is thus the most reproducible metric for liver uptake. The commonly recommended 3 cm diameter spherical VOI-based SUVmean(liver) values were only slightly more variable than those seen with larger VOI sizes and are sufficient for SUVmean(liver) measurements in future studies. TRIAL REGISTRATION: EudraCT: 2006-005,174-42, 01-08-2008.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。